The Renal Drug Handbook, 3rd Edition

Product Information

Summary of Product Characteristics: Diflucan 40 mg/ml powder for oral suspension. Pfizer Ltd. Revised May 2022. Invasive candidiasis: 800mg on day 1, followed by 400mg daily. Treatment duration for candidaemia is two weeks after first negative blood culture result and resolution of signs and symptoms of infection. Oropharyngeal and oesophageal candidiasis: 200mg to 400mg loading dose on first day followed by 100mg to 200mg daily. Altered pharmacokinetics of some drugs, i.e. changes in absorption, tissue distribution, extent of plasma protein binding, metabolism and excretion. In renal impairment these parameters are often variable and interrelated in a complex manner. This may be further complicated if the patient is undergoing renal replacement therapy.

Summary of Product Characteristics: Diflucan 10 mg/ml powder for oral suspension. Pfizer Ltd. Revised May 2022. Avoid using oral potassium supplements in patients with serum potassium greater than 3.5 mEq/l. The recommended monitoring for potassium and creatinine is 1 week after initiation or increase in dose of spironolactone, monthly for the first 3 months, then quarterly for a year, and then every 6 months. Pregnancy and Lactation Pregnancy Summary of Product Characteristics: Spironolactone Tablets 50mg. Actavis UK Ltd. Revised June 2014. Glomerular filtration rate less than 10ml/minute: 20% or normal dose and titrate to response. AdministrationIt is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management. Patients who tolerate 25mg once daily may have their dose increased to 50mg once daily as clinically indicated. Patients who do not tolerate 25mg once daily may have their dose reduced to 25mg every other day.

Acute or recurrent vaginal candidiasis, candidal balanitis. Consider treatment of partners who present with symptomatic genital candidiasis. Newborns at risk of glucose-6-phosphate dehydrogenase deficiency should not be breastfed until this disease can be ruled out. Initial dose: 25mg once daily if serum potassium is less than or equal to 5mEq/l and serum creatinine is less than or equal to 2.5mg/dl.provide healthcare professionals with a single reference of easily retrievable, practical information relating to drug use, sourced from the practical experience of renal units throughout the UK. By referring to the monographs, the user is guided in how to prescribe, prepare and administer the drug with due regard to potentially serious drug interactions and to any renal replacement therapy the patient may be undergoing. The manufacturer advises that mothers should not receive this treatment whilst breastfeeding. Briggs suggests due to the prolonged nature of the therapy, the potential for serious toxicity in a nursing infant may be increased. Summary of Product Characteristics: Quinine Sulfate Tablets 300mg. Teva UK Ltd. Revised April 2012.